Form 4: Cytosorbents Corp Director Alan D. Sobel Reports Stock Option Grant

Director Alan D. Sobel reports the acquisition of 22,000 stock options in Cytosorbents Corp.

Summary

• On April 2, 2024, Alan D. Sobel, a director of Cytosorbents Corp, was granted 22,000 stock options.
• The exercise price of these options is $0.955.
• The options were granted under the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan.
• The options vest in four equal quarterly installments over one year, contingent upon continued service.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, which is neutral in sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and value creation.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule of quarterly installments over one year is a typical arrangement to incentivize continued service and performance.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates